Early-stage funding for European life sciences companies

We are a venture capital firm specialised in seed investment for innovative early stage companies. BGV generally acts as lead investor. Our current portfolio comprises of biotech developing truly disruptive solutions for high unmet medical needs.

Acerta, a multi-billion Euro success story

BioGeneration was co-founder and investor in the most successful biotech startup in Europe: Acerta Pharma. Acerta Pharma has developed Calquence® (acalabrutinib), a drug now approved by the FDA for the treatment of hematologic malignancies (leukemia). Acerta was sold to AstraZeneca for up to US$ 7 billion in 2016.

Shaping new life-science ventures

We gained our experience from working within small and large pharma and biotech companies. Based on this experience and through our extensive industry network, we are able to bring a range of sector-relevant expertise to help accelerate product development and shape the companies to become attractive investment opportunities for the industry.

Latest news

FIRST completes its investment in TargED for the development of Microlyse – a next-generation thrombolytic clot-busting drug

Nov 24, 2020

November 24th, 2020, Utrecht, the Netherlands TargED Biopharmaceuticals, a biotech spin-off of the University Medical Center Utrecht founded by Associate prof. Coen Maas, PhD, Steven de Maat, PhD, Marc van Moorsel and Kristof Vercruysse, raised EUR 1.35 million to...

NorthSea Therapeutics doses first patient in Phase 1 trial of SEFA-1024 in dyslipidemia and further expands its clinical pipeline

Nov 19, 2020

• NST becomes a multi-asset clinical development company, beyond NASH• Pre-clinical studies have demonstrated broad and marked beneficial effects of SEFA-1024 on non-HDL cholesterol, triglycerides, and HDL cholesterol and glycemic control• A third clinical development...

CatalYm raises EUR50 million to advance GDF-15 antibody into clinical trials for checkpoint-inhibitor refractory patients

Nov 10, 2020

Munich, Germany, November 10, 2020 - CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, today announced the closing of its EUR50 million Series B financing round. The financing was led by Vesalius Biocapital III and joined by Novartis...

Confo Therapeutics Announces Selection of First Product Candidate and Initiation of Pre-Clinical Development

Oct 15, 2020

Ghent, Belgium – October 15, 2020 - Confo Therapeutics today announced the selection of its first preclinical drug candidate, CFTX-1554, a compound designed to address peripheral neuropathic pain with the potential to address additional pain indications. Confo has...

News overview

Next events

11-15 January 2021: Biotech Showcase

Nov 19, 2020

The BGV team will be attending at the Biotech Showcase Find more information here

Event overview

Latest investments

Portfolio